DE69719360D1 - Zusammensetzungen und methoden zur steigerung der darmfunktion - Google Patents

Zusammensetzungen und methoden zur steigerung der darmfunktion

Info

Publication number
DE69719360D1
DE69719360D1 DE69719360T DE69719360T DE69719360D1 DE 69719360 D1 DE69719360 D1 DE 69719360D1 DE 69719360 T DE69719360 T DE 69719360T DE 69719360 T DE69719360 T DE 69719360T DE 69719360 D1 DE69719360 D1 DE 69719360D1
Authority
DE
Germany
Prior art keywords
methods
increasing
glp
compositions
bowel function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69719360T
Other languages
English (en)
Other versions
DE69719360T2 (de
Inventor
J Drucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1149336 Ontario Inc
Original Assignee
1149336 Ontario Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1149336 Ontario Inc filed Critical 1149336 Ontario Inc
Application granted granted Critical
Publication of DE69719360D1 publication Critical patent/DE69719360D1/de
Publication of DE69719360T2 publication Critical patent/DE69719360T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69719360T 1996-12-10 1997-12-10 Zusammensetzungen und methoden zur steigerung der darmfunktion Expired - Lifetime DE69719360T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/763,177 US5952301A (en) 1996-12-10 1996-12-10 Compositions and methods for enhancing intestinal function
PCT/CA1997/000945 WO1998025644A1 (en) 1996-12-10 1997-12-10 Compositions and methods for enhancing intestinal function

Publications (2)

Publication Number Publication Date
DE69719360D1 true DE69719360D1 (de) 2003-04-03
DE69719360T2 DE69719360T2 (de) 2003-12-04

Family

ID=25067085

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69719360T Expired - Lifetime DE69719360T2 (de) 1996-12-10 1997-12-10 Zusammensetzungen und methoden zur steigerung der darmfunktion

Country Status (10)

Country Link
US (1) US5952301A (de)
EP (1) EP0944396B1 (de)
AT (1) ATE233096T1 (de)
AU (1) AU5220098A (de)
CA (1) CA2274596C (de)
DE (1) DE69719360T2 (de)
DK (1) DK0944396T3 (de)
ES (1) ES2193406T3 (de)
PT (1) PT944396E (de)
WO (1) WO1998025644A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025933A1 (en) * 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
EP0981362B1 (de) * 1997-05-16 2003-11-05 1149336 Ontario Inc. Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
CA2819705C (en) * 1998-02-02 2014-07-08 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
WO1999058144A1 (en) * 1998-05-11 1999-11-18 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
AU5480199A (en) * 1998-08-21 2000-03-14 Point Therapeutics, Inc. Regulation of substrate activity
GB9906714D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for improving fertility
GB9906715D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
EP1806138A1 (de) * 1999-05-25 2007-07-11 Point Therapeutics, Inc. Anti-tumor präparate enthaltend boroprolin verbindungen
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
HK1046846A1 (zh) * 1999-05-25 2003-01-30 Point Therapeutics, Inc. 包含boroproline的抗肿瘤复合物
DE60037535D1 (de) * 1999-11-03 2008-01-31 Novo Nordisk As Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion
AU3641401A (en) 1999-11-05 2001-05-14 Joseph A. Rogoff Secretin and secretin pharmaceuticals for treating lactose intolerance
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US20070135345A1 (en) * 2000-09-18 2007-06-14 Henriksen Dennis B Use of GLP-2 for the treatment or prevention, of bone-related disorders
JP5161412B2 (ja) 2000-09-18 2013-03-13 サノス・バイオサイエンス・アクティーゼルスカブ Ｇｌｐ−１及びｇｌｐ−２ペプチドの使用方法
US20080249016A1 (en) * 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US7371721B2 (en) * 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
EP1360202B1 (de) * 2001-02-16 2008-05-21 ConjuChem Biotechnologies Inc. Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
US7727964B2 (en) 2001-11-26 2010-06-01 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
WO2003045228A2 (en) * 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
WO2004035624A2 (en) * 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
WO2005047297A1 (en) * 2003-11-12 2005-05-26 Phenomix Corporation Heterocyclic boronic acid compounds
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CA2573209A1 (en) * 2004-07-14 2006-01-19 Novartis Ag Combination of dpp-iv inhibitors and compounds modulating 5-ht3 and/or 5-ht4 receptors
CN102659938B (zh) 2005-05-04 2016-01-20 西兰制药公司 胰高血糖素样肽-2（glp-2）类似物
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
BRPI0718566A2 (pt) 2006-11-08 2014-03-11 Zealand Pharma As Peptídeo, análogo do mesmo, composição farmacêutica, usos de um análogo de peptídeo, e de uma molécula de ácido nucléico, de um vetor de expressão, ou de uma célula hospedeira, molécula de ácido nucléico, vetor de expressão, célula hospedeira, métodos para produzir o análogo de peptídeo-2 tipo-glucagon (glp-2), e, kit terapêutico.
US20110295151A1 (en) * 2010-05-26 2011-12-01 Bakos Gregory J Enteroendocrine Manipulation for Metabolic Effect
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
WO2015006228A1 (en) 2013-07-08 2015-01-15 The University Of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders
EP3299023A4 (de) * 2015-05-21 2019-03-20 Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences Sauerstoffarm behandelte mesenchymale stammzelle und deren verwendung
CN106589110B (zh) * 2015-10-15 2020-01-17 上海迈迹生物医药科技有限公司 包含聚合物和glp-2衍生物的缀合物
SG11201903938XA (en) 2016-12-09 2019-05-30 Zealand Pharma As Acylated glp-1/glp-2 dual agonists
DK3638291T3 (da) 2017-06-16 2021-10-18 Zealand Pharma As Dosisregimer til indgivelse af glucagon-lignende-peptid-2 (GLP-2)-analoger

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288703A (en) * 1991-10-07 1994-02-22 Brigham And Women's Hospital Method for enhancing gut absorption
NZ243071A (en) * 1992-06-08 1994-09-27 Kabi Pharmacia Ab Igf-2 (or analogue) compositions for pharmaceutical uses
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP2218734B1 (de) * 1996-04-12 2013-06-05 1149336 Ontario Inc. Analoge des Glucagon ähnlichen Peptides-2

Also Published As

Publication number Publication date
DK0944396T3 (da) 2003-06-23
DE69719360T2 (de) 2003-12-04
AU5220098A (en) 1998-07-03
EP0944396A1 (de) 1999-09-29
PT944396E (pt) 2003-07-31
CA2274596C (en) 2004-11-09
WO1998025644A1 (en) 1998-06-18
US5952301A (en) 1999-09-14
CA2274596A1 (en) 1998-06-18
EP0944396B1 (de) 2003-02-26
ATE233096T1 (de) 2003-03-15
ES2193406T3 (es) 2003-11-01

Similar Documents

Publication Publication Date Title
DE69719360D1 (de) Zusammensetzungen und methoden zur steigerung der darmfunktion
DK0981362T3 (da) Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal
DE69736634D1 (de) Antagonisten des intestinotrophen glp-2 peptides
EP2295453A3 (de) Appetithemmendes Peptid, Zusammensetzung und Verwendung
EA200000445A1 (ru) Способы лечения состояния гиперкоагуляции или приобретенной недостаточности белка c
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
ATE410441T1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidinanalogen
ATE288444T1 (de) Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
MXPA05002991A (es) Analogos de ghrh.
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
ATE232700T1 (de) Implantatkörper
BR0111506A (pt) Complexos de droga macromoleculares e composições contendo os mesmos
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
BR0213536A (pt) Formulações de xarope de ribavirina
PE20050665A1 (es) ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
ZA984838B (en) Bacterial pheromones and uses therefor.
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento
WO2004083241A3 (en) Btc-interacting proteins and use thereof
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
EP0917535A4 (de) Neuroaktive peptide
DE60030270D1 (de) Fettsaure analoge zur diagnose von kranzarterie erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition